World's key bone, muscle and joint congress to be held in Milan, Italy

December 04, 2014

Musculoskeletal conditions affect over 1.7 billion people around the world. Disability due to these disorders has increased by more than 45% since 1990 - posing a growing challenge to health authorities and health professionals worldwide. In 2015 researchers and clinicians will convene in Milan, Italy for the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO MILAN 2015). This is the key annual forum for the presentation of new research and clinical advances in the fight against these serious and costly diseases.

The Congress, hosted by the International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), will be held from March 26-29, 2015. Abstracts will be accepted until January 15, 2015.

Professor John A. Kanis, IOF President and Co-chair of the Congress stated, "As the largest clinical and research forum in the bone, muscle and joint arena, this is the ideal Congress at which to present new clinical research and share findings with the field's key opinion leaders. There has been a surge of exciting new research in the field and, as in past years, we are expecting approximately 800 research abstracts to be submitted for publication and presentation at poster and oral sessions on site."

Being well-established as an annual forum for clinical education, WCO-IOF-ESCEO MILAN 2015 has applied for European CME accreditation.

Professor Jean-Yves Reginster, President of ESCEO and Co-chair of the Congress said, "The Scientific Committee has planned a highly informative and qualitative programme which will offer delegates insights into new advances and the latest clinical research findings. There will be plenary lectures and topical symposia on 'hot' topics, as well as educational lectures, workshops and Meet-the-Expert sessions. Delegates will have the opportunity to meet colleagues from around the world and will return home with valuable knowledge of benefit to patient care."

Complete information about the Congress is available at

Note these key dates:

Early Registration: December 5, 2014
Pre-registration: December 5, 2014 - March 5, 2015
Abstract submission deadline: January 15, 2015
About IOF

The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers, leading companies, as well as more than 230 patient, medical and research societies, work together to make bone, joint and muscle health a worldwide heath care priority. / /


The European Society for Clinical & Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception.

International Osteoporosis Foundation

Related Osteoporosis Articles from Brightsurf:

New opportunities for detecting osteoporosis
Osteoporosis can be detected through low dose computed tomography (LDCT) imaging tests performed for lung cancer screening or other purposes.

Oxytocin can help prevent osteoporosis
In a laboratory experiment with rats, Brazilian researchers succeeded in reversing natural processes associated with aging that lead to loss of bone density and strength.

New strategy against osteoporosis
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

New review on management of osteoporosis in premenopausal women
An IOF and ECTS Working Group have published an updated review of literature published after 2017 on premenopausal osteoporosis.

Cardiac CT can double as osteoporosis test
Cardiac CT exams performed to assess heart health also provide an effective way to screen for osteoporosis, potentially speeding treatment to the previously undiagnosed, according to a new study.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

New pharmaceutical target reverses osteoporosis in mice
Biomedical engineers at Duke University have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.

A link between mitochondrial damage and osteoporosis
In healthy people, a tightly controlled process balances out the activity of osteoblasts, which build bone, and osteoclasts, which break it down.

Many stroke patients not screened for osteoporosis, despite known risks
Many stroke survivors have an increased risk of osteoporosis, falls or breaks when compared to healthy people.

Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.

Read More: Osteoporosis News and Osteoporosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to